Back to School Savings: Save up to 30% on print books and eBooks. No promo code needed.
Back to School Savings: Save up to 30%
BioIndustry Ethics
1st Edition - June 10, 2005
Authors: David L. Finegold, Cecile M Bensimon, Abdallah S. Daar, Margaret L. Eaton, Beatrice Godard, Bartha Maria Knoppers, Jocelyn Mackie, Peter A. Singer
eBook ISBN:9780080492513
9 7 8 - 0 - 0 8 - 0 4 9 2 5 1 - 3
This book is the first systematic, detailed treatment of the approaches to ethical issues taken by biotech and pharmaceutical companies. The application of genetic/genomic… Read more
Purchase Options
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code is needed.
This book is the first systematic, detailed treatment of the approaches to ethical issues taken by biotech and pharmaceutical companies. The application of genetic/genomic technologies raises a whole spectrum of ethical questions affecting global health that must be addressed. Topics covered in this comprehensive survey include considerations for bioprospecting in transgenics, genomics, drug discovery, and nutrigenomics, as well as how to improve stakeholder relations, design ethical clinical trials, avoid conflicts of interest, and establish ethics advisory boards. The expert authors represent multiple disciplines including law, medicine, bioinformatics, pharmaceutics, business, and ethics.
Advanced undergraduate and graduate students in courses focusing on biotechnology in business, law medicine, biology and public health; Managers and employees in biotech and pharmaceutical companies as well as venture capitalists and financial analysts
RESEARCH TEAM
PREFACE
ACKNOWLEDGMENTS
Chapter 1: INTRODUCTION
Publisher Summary
ETHICAL ISSUES CONFRONTING BIOSCIENCE COMPANIES
WHY SHOULD BIOSCIENCE FIRMS CARE ABOUT ETHICS?
ETHICISTS AND THE BIOSCIENCE INDUSTRY
A NEW APPROACH: BIOSCIENCE BUSINESS ETHICS
STRUCTURE OF THE BOOK
Chapter 2: MERCK: STAYING THE COURSE
Publisher Summary
INTRODUCTION
FOCUSING ON PATIENTS AND THE LONG TERM
ETHICS RESOURCE CENTERS
INTERNAL ETHICAL PRACTICES
ASSESSING THE IMPACT
BENEFITS OF AN ETHICAL APPROACH
ETHICAL ISSUES
DRUG PRICING, ACCESS, AND INTELLECTUAL PROPERTY
CLINICAL TRIALS AND PUBLICATION OF RESULTS
WHAT DRUGS TO DEVELOP
CHALLENGES FOR THE FUTURE
Chapter 3: GENZYME: PUTTING PATIENTS FIRST
Publisher Summary
INTRODUCTION
PUTTING THE PATIENT FIRST: GENZYME’S APPROACH TO ETHICAL ISSUES
ETHICAL ISSUES
DRUG PRICING, MARKETING, ACCESS
CLINICAL TRIALS
PERSONAL CONFLICTS OF INTEREST
PRODUCT MIX
ETHICAL MECHANISMS
SUSTAINING THE GENZYME CULTURE
CONCLUSION
Chapter 4: MILLENNIUM PHARMACEUTICALS, INC.: CREATING AND SUSTAINING CORPORATE VALUES
Publisher Summary
INTRODUCTION
MILLENNIUM PHARMACEUTICALS INC.
INSTITUTIONALIZING CORE VALUES AND ETHICS
ETHICS EDUCATION PROGRAMS
IMPACT OF INSTITUTIONALIZATION OF VALUES AND ETHICS
Chapter 5: MAXIM PHARMACEUTICALS (A): INTERNAL AND EXTERNAL DIALOGUES
Publisher Summary
AN UNUSUAL BIOTECH LEADER
THE IMPACT OF BUSINESS ETHICS IN THE BIOSCIENCE INDUSTRY
COMPANY HISTORY
EMBEDDING CORE VALUES
MECHANISMS FOR EMBEDDING CORE VALUES
BUILDING A SUCCESSFUL GLOBAL BOARD
ANNUAL STRATEGIC RETREAT
DEALING WITH ETHICAL ISSUES
MAXIM PHARMACEUTICALS (B)
Chapter 6: DIVERSA INC.: ETHICAL ISSUES IN BIOPROSPECTING PARTNERSHIPS
Publisher Summary
FROM BIOPIRACY TO BIOPROSPECTING
THE COMPANY
THE CONTEXT FOR BIOPROSPECTING PARTNERSHIPS
DIVERSA’S BIODIVERSITY COLLABORATIONS
PROCESS FOR ESTABLISHING AND IMPLEMENTING COLLABORATIVE AGREEMENTS